Early tumour shrinkage (ETS), defined as a reduction of at least 20% in tumour size at first reassessment, has been recently investigated retrospectively in first-line trials of metastatic colorectal cancer (CRC), and appears to be associated with better outcomes. We have performed a systematic review and meta-analysis of published trials to evaluate the prognostic value of ETS in CRC in terms of overall survival (OS) and progression-free survival (PFS).
Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer : a systematic review and pooled-analysis / F. Petrelli, F. Pietrantonio, C. Cremolini, M. Di Bartolomeo, A. Coinu, V. Lonati, F. de Braud, S. Barni. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 1879-0852. - 51:7(2015 May), pp. 800-807. [10.1016/j.ejca.2015.02.011]
Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer : a systematic review and pooled-analysis
F. PietrantonioSecondo
;F. de BraudPenultimo
;
2015
Abstract
Early tumour shrinkage (ETS), defined as a reduction of at least 20% in tumour size at first reassessment, has been recently investigated retrospectively in first-line trials of metastatic colorectal cancer (CRC), and appears to be associated with better outcomes. We have performed a systematic review and meta-analysis of published trials to evaluate the prognostic value of ETS in CRC in terms of overall survival (OS) and progression-free survival (PFS).
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S0959804915002117-main.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
736.92 kB
Formato
Adobe PDF
|
736.92 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
